“Lenvatinib is More Effective & Safer Than Sorafenib in the Treatment of Renal Cell Carcinoma - A Single-Center Retrospective Analysis of 70 Cases”, JOC, vol. 23, no. 1, pp. 624–628, Dec. 2024, doi: 10.64149/J.Carcinog.23.1.624-628.